Rocco, N. et als.
Cochrane Database of Systematic Reviews 2016 Issue 5. Art. No.: CD010895
El cáncer de mama es el cáncer más frecuente en las mujeres en todo el mundo y es la principal causa de muerte por cáncer entre las mujeres. La mastectomía profiláctica o curativa a menudo está seguida por la reconstrucción de la mama, por lo que existen varios enfoques quirúrgicos que utilizan implantes de mama con los que los cirujanos pueden restaurar la apariencia, el tamaño y la forma natural de la mama. El objetivo de este trabajo fue evaluar los efectos de diferentes tipos de implantes de mama sobre la contractura capsular, las complicaciones quirúrgicas a corto y a largo plazo, el nivel de satisfacción posoperatoria y la calidad de vida en las pacientes sometidas al proceder.
The majority of studies assessing the rupture rate of breast implants were performed by the breast implant manufacturing industry with questionable independence. After repetitive removals of ruptured implants from the same model, our team decided to assess the rupture rate and the estimated risk thereof for most of the silicone gel–filled implants we have used since they regained market approval in France in 2001.
In March of 2013, the Executive Committee of the American Society of Plastic Surgeons approved an evidence-based guideline on breast reconstruction with expanders and implants, as developed by a guideline-specific work group commissioned by the society’s Health Policy Committee. The guideline addresses ten clinical questions: patient education, immediate versus delayed reconstruction, risk factors, radiation therapy, chemotherapy, hormonal therapy, antibiotic prophylaxis, acellular dermal matrix, monitoring for cancer recurrence, and oncologic outcomes associated with implant-based reconstruction.
Breast reduction is well-known to provide an improvement in physical symptoms. However, measurements show that this procedure is less effective in restoring upper-pole fullness. Breast implants effectively augment the upper pole. This study was undertaken to determine the effectiveness and safety of this treatment combination.
Late haematomas and seromas (≥4 months postoperatively) in breasts with silicone prosthesis have been reported. Since 2001, there have only four patients with such delayed complication visiting our hospitals. The purpose of this literature review and our case presentation is to have more understanding about the clinical symptoms, surgical managements and relationship with implants for this late complication.
Despite increased cases published on breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), important clinical issues remain unanswered. We conducted a second structured expert consultation process to rate statements related to the diagnosis, management, and surveillance of this disease, based on their interpretation of published evidence.
Sitio web publicado el
Los lectores comentan